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Introduction
Children with sickle cell disease (SCD) are at an 
increased risk for stroke.1-3 Without intervention, 11% of 
children with SCD are expected to have a stroke by the 
age of 20 years; however, the majority of these strokes 
are now considered preventable.4-6 Transcranial Doppler 
(TCD) screening detects blood velocities in cerebral 
vessels; high velocities are indicative of a high stroke 
risk and indicate the need to begin preventive efforts in 
the form of blood transfusions to maintain low hemoglo-
bin (Hb) concentrations.7
The Stroke Prevention in Sickle Cell Anemia (STOP) 
trial in 1998 found that stroke risk was reduced by 92% 
in children receiving chronic blood transfusions after 
detection of high blood velocities by TCD screening as 
compared with those not receiving transfusions.8 The 
National Heart, Lung and Blood Institute (NHLBI) 
released guidelines in 2002 recommending that TCD 
screening be initiated for children with SCD at 2 years 
old, and if TCD results show normal blood velocities, 
children are recommended to subsequently receive 1 
screening annually until 16 years old.9 This recommen-
dation was further emphasized in 2014 with newly 
released NHLBI guidelines, which continue to strongly 
recommend TCD screening among children with SCD.10
Health care use is often high in children with SCD 
because this population has 7 to 30 times the hospitaliza-
tion rates, 2 to 6 times the emergency department (ED) 
visits, and more than 8 times the health care expenditures 
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compared with their counterparts without SCD.11-14 Even 
with frequent contact with the health care system, TCD 
screening rates are still substantially lower than that rec-
ommended by the NHLBI guidelines.15,16 One contribut-
ing factor may be missed opportunities for TCD screening, 
where a child with SCD who is eligible for screening has 
a health service encounter, yet does not have a TCD 
screen performed. This missed opportunity framework 
has been utilized successfully in the immunization litera-
ture to identify interventions to increase immunization 
rates.17,18 To our knowledge, missed opportunities have 
never been explored in relation to TCD screening in chil-
dren with SCD; however, we hypothesized that missed 
opportunities for TCD screening may be numerous in 
children with SCD and provide an appropriate interven-
tion target, given the frequent health care interactions and 
low TCD screening rates among children with SCD. 
Therefore, the objectives of this study were to (1) assess 
TCD screening rates, (2) calculate the frequency and pre-
dictors of missed opportunities for TCD screening in chil-
dren with SCD enrolled in Michigan Medicaid, and (3) 
estimate the maximum TCD screening rates potentially 
achievable through reductions in missed opportunities 
based on these findings.
Methods
Data Sources
Administrative data from Michigan Medicaid for the years 
2007 to 2011 were queried from the Michigan Department 
of Health and Human Services (MDHHS) data warehouse, 
including enrollment history and claims for inpatient, ED, 
outpatient, and pharmacy services. Michigan Medicaid 
enrollees were linked to newborn screening results through 
birth certificates to identify children with SCD born from 
1987 to 2008, and all administrative claims were obtained 
for children with SCD.19
Study Population
Children 2 to 16 years of age with SCD were identified as 
those having HbSS or HbS/βthalassemia.8-10 Children were 
eligible for the study if they were continuously enrolled in 
Michigan Medicaid with no other forms of health insur-
ance for at least 1 calendar year (January 1 to December 
31) from 2007 to 2011; a 1-month gap in enrollment was 
allowed each year. Children with receipt of 6 or more blood 
transfusions in a year were excluded because transfusions 
may be indicative of prior stroke or high blood velocities as 
detected by previous TCD.7,8 Blood transfusions were 
identified through CPT codes of 09882, 09883, 36430, 
36455, 86999, S3906, or S9538 on any claim. Children 
with unknown date of birth were also excluded.
Receipt of TCD Screening and Presence of 
Missed Opportunities for TCD Screening
Two outcomes were identified for each year the child 
was in the study population: (1) receipt of at least 1 TCD 
screening and (2) presence of a missed opportunity for 
TCD screening. Receipt of TCD screening was defined 
as having any claim with a CPT code of 93886, 93888, 
93890, 93892 or 93893.20 A missed opportunity was 
defined as having an SCD-related outpatient visit with 
no receipt of TCD screening within the same year.21 
Consistent with other studies, we included diagnosis 
codes in any position for sickle cell anemia (282.60, 
282.61, and 282.62) and HbS/βthalassemia (282.41 and 
282.42) as well as HbSC (282.63 and 282.64) and HbSD 
(282.68 and 282.69).22-24
Correlates of Missed Opportunities
Identification of correlates of missed opportunities may 
detect specific subgroups of children that could be tar-
geted to reduce missed opportunities. We identified a 
subset of children within our study population who were 
enrolled for at least 2 consecutive years in Michigan 
Medicaid from 2007 to 2011 (children could contribute 
multiple time intervals). Two consecutive years of enroll-
ment was required to ensure that the potential correlates 
occurred prior to the missed opportunity (ie, to preserve 
the temporal relationship). We investigated the following 
correlates: SCD-related health care encounters (ED, 
inpatient, outpatient, and hematologist visits), SCD 
comorbidities (pneumococcal infection and severity of 
disease),15 previous receipt of TCD screening, sickle cell 
subtype (HbSS, HbS/βthalassemia), and demographics 
(age, sex). With the exception of age, all correlates were 
characterized in the first year of continuous enrollment, 
and the presence of a missed opportunity was assessed in 
the following year (year 2 of continuous enrollment). 
Children with no SCD-related outpatient visits in year 2 
were excluded from this analysis.
Pneumococcal infection was identified as any nonpre-
ventive health care claim with an ICD-9 code of 038.0, 
038.2, 481, 482.3, 482.9, or 486.25 A proxy for severity of 
disease was determined using the number of inpatient 
visits per year with children: 2 or more inpatient visits 
was considered indicative of severe SCD.15 ED, inpa-
tient, and outpatient (both preventive and nonpreventive) 
visits were identified using the ICD-9 CM codes for 
SCD. Hematologist visits were defined as having at least 
1 visit in Medicaid claims with a hematologist identified 
through (1) pediatric hematologists from the American 
Medical Association (AMA) Masterfile or (2) an Internet 
search of pediatric hematologists; subsequently, all 
hematologists were verified as a board-certified 
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hematologist using the National Provider Index (NPI). 
Previous receipt of TCD screening was identified through 
CPT codes for TCD as described above and also mea-
sured in year 1 of continuous enrollment. Age and sex 
were from Medicaid eligibility files; age was determined 
as the child’s age on January 1 of the second year of con-
tinuous enrollment. Sickle cell type was defined as either 
HbSS or HbS/βthalassemia as obtained from newborn 
screening records.
Statistical Analysis
Frequencies and percentages or means and standard 
deviations (SDs) were determined for all demographics. 
The proportion of children receiving TCD screening 
was calculated annually (2007-2011) and by age groups 
of 2 to 6 years, 7 to 11 years, and 12 to 16 years. The 
proportion of missed opportunities was calculated annu-
ally and for the overall study period. The maximum 
potentially achievable TCD screening rate was esti-
mated for 25%, 50%, 75%, and 100% reductions in 
missed opportunities based on TCD screening rates and 
missed opportunities in 2011.
Frequencies and percentages or means and SDs were 
calculated for potential correlates of a missed opportu-
nity. Logistic regression with generalized estimating 
equations (GEEs) was used to estimate the association 
between each correlate and the presence of at least one 
missed opportunity. GEE models with robust standard 
errors were estimated to account for the correlation 
within children because each child could contribute 
multiple 2-year time intervals.26 Alternative functional 
forms for continuous variables were investigated; based 
on the Quasi-Akaike Information Criterion for each 
model, we determined that SCD-related inpatient visits, 
ED visits, and age should be modeled as continuous 
variables, whereas SCD-related outpatient visits was 
modeled using indicator variables based on quintiles (1 
visit, 2 visits, 3 visits, 4-5 visits, and 6+ visits).26 
Hematologist visits and pneumococcal infection were 
included as dichotomous variables, in addition to sickle 
cell subtype (HbSS vs HbS/βthalassemia), sex (male vs 
female), severity of disease, and previous receipt of 
TCD screening. Covariates showing an association (P < 
.20) with a missed opportunity were included in a final 
multivariable model.
The study was approved by the institutional review 
board of the University of Michigan (#HUM00051878).
Results
A total of 638 children with HbSS or HbS/βthalassemia 
born between 1987 and 2008 were identified in Michigan 
Medicaid claims from 2007 to 2011. Among these chil-
dren, 40 (6.2%) were missing date-of-birth information. 
An additional 124 children (19.4%) were not continu-
ously enrolled for at least 1 year, for a total of 474 chil-
dren contributing 1831 person-years of enrollment. 
From 2007 to 2011, 179 person-years were excluded 
because of receipt of at least 6 transfusions, and 586 
person-years did not meet the age requirement of 2 to 16 
years. The final study population consisted of 353 
unique children contributing 1066 person-years. Among 
the 353 eligible children, 85 contributed 1 year of enroll-
ment (24%), 67 contributed 2 years (19%), 56 contrib-
uted 3 years (16%), 46 contributed 4 years (13%), and 
99 contributed 5 years of enrollment (28%). In 2007, 
among 231 eligible children, the average age was 10.5 
years (SD = 4.1); 50% were female; and 87% were 
sickle cell subtype HbSS (Table 1).
TCD Screening and Missed Opportunities
Overall, 159 of 353 eligible children (45%) received 
screening at least once from 2007 to 2011. Receipt of 
TCD screening was low each year (10% to 32%), 
although the proportion of children receiving TCD 
screening did increase over the study period (Figure 
1). Children 2 to 6 years old had the highest likelihood 
of screening (38%), and rates decreased with increas-
ing age; 20% of children 7 to 11 years old and 14% of 
12- to 16-year-olds received screening from 2007 to 
2011.
A total of 196 person-years did not include a SCD-
related outpatient visit and were excluded, resulting in 
307 children contributing 870 person-years for quanti-
fication of missed opportunities. The frequency of 
missed opportunities was high, ranging from 61% to 
88% per year; 73% of all person-years contained a 
missed opportunity (Figure 2).
Table 1. Baseline Demographics of Children With Sickle 
Cell Disease Enrolled in Michigan Medicaid in 2007, n = 231.
n (%) or Mean (SD)
Gender
 Male 115 (50)
 Female 116 (50)
Race
 Black 222 (96)
 White 2 (1)
 Unknown 7 (3)
Sickle cell subtype
 Hemoglobin SS 201 (87)
 Hemoglobin S/βthalassemia 30 (13)
Age on January 1, 2007 (years) 10.5 (4.1)
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Figure 2. Frequency of missed opportunities in children 
enrolled in Michigan Medicaid for at least 1 year, from 2007 
to 2011, with sickle cell disease and at least 1 sickle cell 
disease–related outpatient visit.
Increasing Screening Rates Through 
Reduction of Missed Opportunities
Based on 2011 rates (63% of children had a missed oppor-
tunity; 32% of children received TCD screening), a 25% 
reduction in missed opportunities would correspond to a 
45% TCD screening rate among children with SCD. 
Similarly, a reduction in missed opportunities by 50% 
would lead to a TCD screening rate of 58% and by 75% to 
a screening rate of 72%; complete elimination of missed 
opportunities would lead to a screening rate of 85%.
Correlates of Missed Opportunities
A subset of 249 children (74%) was enrolled for at least 
2 consecutive years and met eligibility criteria for analy-
sis of potential correlates of missed opportunities. SCD-
related health care encounters and presence of SCD 
comorbidities were relatively constant from 2007 to 
2011; the majority had at least 1 hematologist visit in the 
first year of continuous enrollment; 12% to 20% had a 
pneumococcal infection; and 32% to 39% had at least 2 
inpatient visits within a year (considered severe SCD; 
Table 2). Presence of a missed opportunity was 
associated with increasing age, previous receipt of TCD 
screening, SCD-related outpatient visits, SCD-related 
inpatient visits, presence of a pneumococcal infection, 
and at least 1 hematologist visit. In the multivariable 
logistic regression GEE model, a 1-year increase in age 
was associated with an increased likelihood of a missed 
opportunity (odds ratio [OR] = 1.11; confidence interval 
[CI] = 1.06, 1.15). Children with previous receipt of 
TCD screening (OR = 0.26; CI = 0.16, 0.41) were less 
likely to have a missed opportunity than those without a 
previous screening, along with children with 4 to 5 out-
patient visits (OR = 0.48; CI = 0.26, 0.87) or 6 or more 
outpatient visits (OR = 0.26; CI = 0.14, 0.49) compared 
with children with 1 outpatient visit (Table 3).
Discussion
TCD screening rates were low among children with SCD 
in the Michigan Medicaid population, although rates 
increased over the study period. Low rates of screening 
combined with frequent interactions with the health care 
system led to a high frequency of missed opportunities 
for screening, particularly in older children. This study 
suggests that even small reductions in missed opportuni-
ties could increase TCD screening rates substantially.
TCD screening rates were low across all ages (10% 
to 32% from 2007 to 2011), with only 14% of children 
12 to 16 years old receiving screening. Previous studies 
in sickle cell centers have demonstrated higher overall 
rates of TCD screening, although a study in a large, 
managed health care plan also showed a trend toward 
increased screening rates in younger compared with 
older children.15,16,27 Our results may be a more accurate 
reflection of screening rates in all children with SCD 
because of inclusion of children up to the age of 16 
years, consistent with NHLBI recommendations.9,10 
Several studies have used administrative claims or a 
recent comprehensive visit for SCD to identify their 
study populations, which biases toward those who seek 
care and thus may be more likely to receive screening. A 
strength of this study is identification of the study popu-
lation using newborn screening records, which allows 
inclusion of children with no SCD-related health care 
encounters (12%-15% per year). This likely contributed 
to our lower rates as compared with those in other stud-
ies. However, our rates of TCD screening may still be an 
underestimation of the true rate of screening among 
children with SCD as a result of the inclusion criterion 
of continuous enrollment for at least 1 year in Medicaid 
because children with gaps in insurance coverage may 
be less likely to receive TCD screening.
High SCD-related health care use coupled with low 
rates of TCD screening led to a high frequency of missed 
opportunities for TCD screening. The increase in missed 
Figure 1. Receipt of transcranial Doppler screening 
among children with sickle cell disease enrolled in Michigan 
Medicaid for at least 1 year, 2007 to 2011.
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opportunities in older children may be partly a result of 
variation across guidelines in the ages recommended for 
TCD screening. Whereas the NHLBI recommends 
screening from ages 2-16, the American Heart Association 
suggests that screening begin at 2 years with more fre-
quent screening in younger patients, with no specific 
guidelines for teenagers, and the American Academy of 
Pediatrics advises discussion of TCD screening for 1- to 
13-year-old children if available.9,28,29,10 Our results dem-
onstrating an association between prior receipt of TCD 
screening and a decreased odds of a missed opportunity 
also indicate that the same children may be receiving 
TCD screening each year. These children may have phy-
sicians who are consistently recommending TCD screen-
ing, or other factors, such as patient knowledge of TCD 
screening or clinic-specific recommendation practices, 
may be leading to more consistent screening.
We hypothesized that increased ED, inpatient, outpa-
tient, and SCD visits and SCD comorbidities would be 
associated with fewer missed opportunities; however, no 
associations were found between these potential correlates 
and missed opportunities, apart from increased outpatient 
visits. This is similar to a recent study that showed that chil-
dren with one or more outpatient visits are 2 to 3 times 
more likely to receive TCD screening than children with-
out an outpatient visit; however, we did not show a reduc-
tion in the odds of a missed opportunity until at least 4 
outpatient visits.27 Children with a high frequency of health 
care use may potentially be a higher-risk group, which may 
positively influence their likelihood of screening.
Other unmeasured factors, such as physician and 
patient barriers, could be playing a role in missed oppor-
tunities apart from the factors investigated in this study. 
Lack of knowledge and/or awareness regarding TCD 
screening guidelines among physicians could be con-
tributing to underrecommendation for TCD screening 
and, therefore, missed opportunities.30,31 Patient barriers 
such as distance to a TCD screening facility and 
Table 2. Health Care Encounters and Comorbidities of Children With Sickle Cell Disease (SCD) Enrolled in Michigan 
Medicaid for at Least 2 Years From 2007 to 2011 and With at Least 1 SCD-Related Outpatient Visit.a
2007-2008, n = 159 2008-2009, n = 151 2009-2010, n = 145 2010-2011, n = 153
 Mean (Standard Deviation)
SCD-related inpatient visits 1.3 (1.7) 1.4 (1.9) 1.4 (1.7) 1.4 (1.9)
SCD-related outpatient visits 3.9 (3.5) 4.1 (3.1) 4.3 (3.6) 4.5 (3.5)
SCD-related emergency department visits 0.7 (1.3) 0.6 (0.9) 0.8 (1.2) 1.0 (1.6)
 n (%)
Pneumococcal infection 19 (12) 25 (17) 29 (20) 19 (12)
Hematologist visit 148 (93) 133 (88) 122 (84) 130 (85)
Severe SCDb 59 (37) 51 (34) 57 (39) 49 (32)
aCovariates measured in year 1 of the 2 years of continuous enrollment.
bAt least 2 inpatient visits within a year.
Table 3. Multivariable Associations With Presence of a Missed Opportunity for TCD Screening in Michigan Medicaid, 2007-2011.
Odds Ratio Confidence Interval P Value
SCD-related outpatient visits 1 Visit Reference Reference  
 2 Visits 1.06 0.49, 2.26 .89
 3 Visits 0.76 0.39, 1.48 .42
 4-5 Visits 0.48 0.26, 0.87 .02
 6+ Visits 0.26 0.14, 0.49 <.0001
Previous TCD screening Yes 0.26 0.16, 0.41 <.0001
 No Reference  
Age 1.11 1.07, 1.15 <.0001
Inpatient SCD visit 1.00 0.90, 1.12 .93
Pneumococcal infection Yes 0.78 0.46, 1.32 .36
 No Reference  
Hematologist visit Yes 1.11 0.55, 2.27 .76
 No Reference  
Abbreviations: SCD, sickle cell disease; TCD, transcranial Doppler.
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appointment adherence could also play a role in receipt 
of TCD screening, regardless of physician recommenda-
tion.15,16,32 Furthermore, caregivers of children with 
SCD have been shown to perceive the stroke risk for 
their child to be low and may not realize the importance 
of TCD screening.33 Additional research is needed to 
explore provider and patient-level factors that may 
influence missed opportunities to identify the most via-
ble intervention targets in this high-risk population.
Reducing missed opportunities may be an appropriate 
strategy to increase TCD screening rates. Although identi-
fication of missed opportunities in immunization studies 
has allowed targeted interventions to increase vaccination 
rates, receipt of TCD screening differs from the receipt of 
a vaccination.17,18 Vaccinations can often occur at the same 
location and time as a doctor appointment, whereas TCD 
screening often occurs off-site and at an appointment dif-
ferent from the contact with the physician. Therefore, 
novel strategies to identify opportunities to reduce missed 
opportunities are necessary. Approaches such as offering 
screening at the same time as a clinic appointment have 
previously been shown to be successful and may be 
acutely needed, given the substantial proportion of chil-
dren with a missed opportunity identified in this study.34
Limitations to this study exist. Medicaid claims data 
were used to identify covariates; therefore, errors in CPT or 
ICD-9 codes could lead to potential misclassification of 
variables. If the screening was performed but the child’s 
insurance was not billed for the TCD screening, receipt of 
TCD screening would have been underreported. However, 
a recent study assessing the accuracy of administrative 
claims demonstrated high sensitivity of claims to identify 
TCD screening when compared with documentation in the 
medical record.35 We were unable to identify reasons for 
the missed opportunity. For example, data were unavail-
able to indicate whether a physician took appropriate clini-
cal action in recommending a TCD screen, but external 
circumstances did not allow for the child’s screen to be 
completed. Although not all children with SCD are enrolled 
in Michigan Medicaid, 70% of children with SCD born 
between 1987 and 2008 had a Medicaid ID, indicating that 
these data do capture the majority of children with SCD in 
Michigan. Finally, there may be other children with SCD in 
Michigan not identified through Michigan’s Newborn 
Screening program; however, through the use of Newborn 
Screening records, we can accurately report that each child 
included in the study population did have SCD.
In conclusion, the proportion of children receiving 
TCD screening each year is low, and missed opportuni-
ties are numerous in children with SCD in the Michigan 
Medicaid population. Increasing age is associated with 
having a missed opportunity, whereas 4 or more SCD-
related outpatient visits and receipt of TCD screening in 
the year prior are protective against missed opportuni-
ties. Identification of novel interventions to reduce 
missed opportunities for TCD screening may be an inte-
gral strategy to increase adherence to TCD screening 
recommendations, thereby reducing the incidence of 
pediatric stroke in this high-risk population.
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